Pulmonx Corporation Reports Q2 2025 Financial Growth

Pulmonx Corporation ( (LUNG) ) has released its Q2 earnings. Here is a breakdown of the information Pulmonx Corporation presented to its investors.

Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), known for its innovative Zephyr® Endobronchial Valve and other related technologies. The company recently released its financial results for the second quarter of 2025, highlighting a 15% increase in worldwide revenue compared to the same period last year, reaching $23.9 million. This growth was driven by a strong international performance, with a 32% increase in international revenue and a 6% increase in U.S. revenue.

Key financial metrics from the report include a gross margin of 72% and a net loss of $15.2 million, slightly improved from the previous year’s net loss of $15.3 million. Pulmonx also reported significant operational achievements, such as the addition of 12 new U.S. treatment centers and the training of 26 new physicians. Despite these advancements, the company revised its full-year revenue guidance to a range of $90 million to $92 million, down from previous expectations.

The company’s strategic focus on building a scalable ecosystem for patient engagement and access is beginning to show promising results. Pulmonx’s efforts in direct-to-patient advertising drove over 20,000 first-time patient engagements, indicating a growing interest and potential for future growth in its target markets.

Looking ahead, Pulmonx remains committed to its long-term growth strategy, despite revising its financial outlook for 2025. The company anticipates continued progress in its international markets and aims to enhance its U.S. revenue conversion efforts, positioning itself for sustained success in the minimally invasive treatment sector.